González PH

Idioma: Español
Referencias bibliográficas: 14
Paginas: 63-68
Archivo PDF: 64.38 Kb.

RESUMEN

El artículo revisa la utilidad de las heparinas en el manejo de pacientes con síndromes coronarios agudos. Las heparinas de bajo peso molecular tienen un número de ventajas sobre la heparina no fraccionada y existen evidencias que son más efectivas que el placebo e igual que la heparina no fraccionada en disminuir la incidencia de infarto agudo del miocardio o de muerte. La evidencia de que las heparinas de bajo peso molecular sean superiores está limitada únicamente a la enoxaparina y el grupo que mayor se beneficia es el estratificado como de alto riesgo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. THEROUX P, FUSTER V: Acute coronary syndromes: unstable angina and non Q-wave myocardial infarction. Circulation 1998; 97: 1195-206.

2. Fragmin During Instability in Coronary Artery Disease (FRISC study group: Low-molecular- weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.

3. WEITZ JI, HIRSH J: New antithrombotic agents. Chest 1998; 114: 715S-727S.

4. OLER A, WHOOLER MA, OLER J, GRADY D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996; 276: 811-815.

5. ALMONY GT, LEFKOVITS J, TOPOL EJ: Antiplatelet and anticoagulant use after myocardial infarction. Clin Cardiol 1996; 19: 357-365.

6. WEITZ JI: Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.

7. FAREED J, JESKIE W, HOPPENSTEADT D, CLARIZO R, WALENGA JM: Are the available lowmolecular- weight heparin preparations the same? Sem Thromb Hemost 1996; 22: 77-91

8. Fragmin During Instability in Coronary Artery Disease (FRISC study group: Low-molecular- weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.

9. KLEIN W, BUCHWALD A, HILLIS SE, ET AL: For the Fric Investigators: Comparison of lowmolecular- weight heparin with unfractionated heparin acutely and with placebo for six week in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-68.

10. The Fraxis Study Group: Comparison of two treatment duration (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAxiparine in Ischaemin Syndrome). Eur Heart J 1999; 20: 1553-1562.

11. COHEN M, DEMERS C, GURFINKEL EP, ET AL: For the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of lowmolecular- weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-452.

12. ANTMAN EM, MCCABE CH, GURFINKEL EP, ET AL: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Qwave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-1601.

13. ANTMAN EM, COHEN M, RADLEY DR, ET AL. For the TIMI-11B and Essence Investigators: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI-11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602- 1608.

14. SANJAY K, PREDIMANK S: Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000; 35: 1699-1712.